Mitoxantrone as a potential therapy for primary progressive multiple sclerosis.
Mitoxantrone (Novantrone) was the first drug approved in western Europe and North America for treatment of secondary progressive multiple sclerosis (SPMS) and progressive relapsing MS (PRMS). Pharmacological properties of mitoxantrone, its role in SPMS, the study rational and design of an ongoing multi-centre, double blind, randomized, placebo-controlled phase 2 trial will be outlined in this article.
Stüve
Olaf
O
Department of Neurology, University of California, San Francisco, 521 Parnassus Avenue, C-440, San Francisco, CA 94143-0114, USA.
Kita
Mariko
M
Pelletier
Daniel
D
Fox
Robert J
RJ
Stone
Jerome
J
Goodkin
Donald E
DE
Zamvil
Scott S
SS
D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008942:Mitoxantrone / Q000627:therapeutic use*; D020528:Multiple Sclerosis, Chronic Progressive / Q000188:drug therapy*
D007166:Immunosuppressive Agents; D008942:Mitoxantrone